top of page
BMCH Website Header.jpg

Papillary Carcinoma of the Thyroid

Endocrine system

Papillary Carcinoma of the Thyroid (PTC)
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, accounting for 80-85% of all thyroid malignancies. It typically has an excellent prognosis, especially when detected early, due to its slow growth and high responsiveness to treatment.

Key Features:
• Epidemiology:
o More common in women, with a peak incidence between 30-50 years.
o Often linked to radiation exposure, especially in childhood.
• Genetics:
o Associated with genetic mutations such as BRAF, RET/PTC rearrangements, and RAS mutations.

Clinical Presentation:
• Thyroid Nodule: Painless, palpable nodule in the neck.
• Lymphadenopathy: Cervical lymph node metastases may be the first sign.
• Hoarseness or Dysphagia: Due to compression or invasion of local structures (less common in early stages).
• Asymptomatic: Often detected incidentally on imaging studies.

Gross Appearance:
• Size and Shape:
o Solitary or multifocal mass.
• Surface:
o Firm, white, or tan, with irregular borders.
• Cut Surface:
o May show cystic areas, calcifications, or fibrosis.
• Psammoma Bodies:
o Gritty texture due to calcified structures commonly found in Papillary Thyroid Carcinoma.

Microscopic Features:
Characteristic Architecture:
o Papillary structures: Finger-like projections with a fibrovascular core lined by epithelial cells.

Nuclear Features (Hallmark):
o "Orphan Annie eye" nuclei: Nuclei with a ground-glass or empty appearance due to dispersed chromatin.
o Nuclear grooves: Longitudinal folds in the nuclear membrane.

o Intranuclear pseudoinclusions: Cytoplasmic invaginations into the nucleus, giving a "bubble" appearance.

Psammoma Bodies:
o Concentric, laminated calcifications seen in 40-50% of cases.
o More common in lymph node metastases.
o
Stroma:
o The stroma may contain areas of fibrosis or hyalinization.
o Chronic inflammatory infiltrates may be present.
o Lymphovascular Invasion:
o Common and often leads to cervical lymph node metastases.
o Capsular Invasion:
o Invasion through the thyroid capsule indicates a more aggressive tumor.

Special Stains and Immunohistochemistry (IHC):
Positive markers:
o Thyroglobulin and TSH receptor (confirm thyroid origin).
o CK19, HBME-1, and Galectin-3 (useful for distinguishing from benign nodules).
o BRAF V600E mutation in aggressive subtypes.
Negative markers:
o Negative for calcitonin (helps rule out medullary carcinoma).

Variants of Papillary Thyroid Carcinoma (PTC)
o Papillary thyroid carcinoma has several histological variants, each with unique features and clinical significance. While the classic variant is the most common, other variants may have distinct prognostic implications.

1. Classic (Conventional) Variant:
Features:
o Papillary architecture with characteristic nuclear features (Orphan Annie eye nuclei, nuclear grooves, and intranuclear inclusions).
Prognosis:
o Excellent prognosis with high survival rates.

2. Follicular Variant (FVPTC):
Features:
o Follicular growth pattern instead of papillary structures.
o Retains the nuclear features of PTC.
Subtypes:
o Encapsulated (better prognosis).
o Invasive (higher risk of recurrence).
Prognosis:
o Generally favorable, but invasive forms behave more aggressively.

o 3. Tall Cell Variant:
Features:
o Composed of tall columnar cells (height at least 2–3 times the width).
o Prominent nuclear features of PTC.
Clinical Behavior:
o More aggressive, with higher rates of extrathyroidal invasion and metastasis.
Prognosis:
o Worse prognosis compared to the classic variant.


4. Diffuse Sclerosing Variant:
Features:
o Extensive sclerosis (fibrosis), numerous psammoma bodies, and lymphocytic infiltration.
o Diffuse involvement of the thyroid.
Clinical Behavior:
o Frequently presents with cervical lymph node metastases.
Prognosis:
o Intermediate to poor prognosis due to early spread and aggressive behavior.

5. Columnar Cell Variant:
Features:
o Composed of tall columnar cells with nuclear stratification.
o Less prominent nuclear features of classic PTC.
Clinical Behavior:
o Aggressive, with high recurrence and metastasis rates.
Prognosis:
o Poorer prognosis compared to classic PTC.

6. Hobnail Variant:
Features:
o Cells have a "hobnail" appearance (bulging apical cytoplasm).
o Aggressive features, often with high mitotic activity.
Clinical Behavior:
o Highly aggressive, with poor outcomes.
Prognosis:
o Poor.


7. Cribriform-Morular Variant:
Features:
o Cribriform and morular (whorl-like) patterns.
o Often associated with familial adenomatous polyposis (FAP).
Prognosis:
o Generally favorable if detected early.

8. Oncocytic (Oxyphilic) Variant:
Features:
o Composed of oncocytic cells (large cells with abundant eosinophilic cytoplasm).
o Retains nuclear features of PTC.
Clinical Behavior:
o More aggressive than the classic variant.
Prognosis:
o Variable, depending on invasiveness.

9. Clear Cell Variant:
Features:
o Cells with clear cytoplasm due to glycogen accumulation.
Clinical Behavior:
o Rare and may behave aggressively.
Prognosis:
o Poorer compared to classic PTC.

10. Solid (Trabecular) Variant:
Features:
o Solid nests or trabecular arrangements of tumor cells.
o Retains nuclear features of PTC.
Clinical Behavior:
o More aggressive, with higher metastatic potential.
o Prognosis:
o Poorer prognosis compared to the classic variant.
o Would you like a summary of treatment strategies tailored for specific variants?
o Follicular variant: Predominantly follicular architecture but with papillary nuclear features.
o Tall cell variant: More aggressive, with tall columnar cells.
o Columnar cell variant: Rare, with columnar cell morphology.

Diagnosis:
• Ultrasound:
o Identifies suspicious thyroid nodules and lymph nodes.
o Features suggestive of malignancy: microcalcifications, irregular margins, hypoechogenicity.
• Fine-Needle Aspiration (FNA):
o Gold standard for evaluating thyroid nodules.
o Bethesda system categorizes findings (Bethesda V or VI suggests malignancy).
• Thyroid Function Tests:
o Usually normal.
• Molecular Testing:
o Detects mutations (e.g., BRAF) that can confirm malignancy and predict prognosis.

Management:
• Surgery:
o Total Thyroidectomy or Lobectomy, depending on the size, extent, and risk factors.
o Lymph node dissection if metastases are present.
• Radioactive Iodine (RAI) Therapy:
o Used post-surgery in high-risk cases to ablate residual thyroid tissue or treat metastatic disease.
• Thyroid Hormone Suppression Therapy:
o Suppresses TSH to reduce the risk of recurrence.
• Follow-Up:
o Thyroglobulin (Tg) Monitoring: A tumor marker for recurrence.
o Neck Ultrasound: Regular imaging to detect recurrences.

Prognosis:
• Excellent in most cases, with a 5-year survival rate over 95%, especially in younger patients and those with localized disease.
• Factors affecting prognosis:
o Age, tumor size, extrathyroidal extension, distant metastases, and specific histological variants.

bottom of page